This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/resource/drugbank/drug/DB01299/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01299/identifier/pubchem-compound/
n5http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01299/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01299/identifier/kegg-drug/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01299/identifier/drugbank/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01299/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01299/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01299/identifier/pharmgkb/

Statements

Subject Item
n2:DB01299
rdf:type
n3:Drug
n3:description
A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. [PubChem]
n3:group
approved
n3:indication
Sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria. It can also be used to treat various infections in livestock as well. Sulfadoxine and pyrimethamine is indicated for the treatment of Plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected.
owl:sameAs
n17:DB01299 n18:DB01299
dcterms:title
Sulfadoxine
adms:identifier
n7:16218 n8:DB01299 n10:9329 n11:PA451540 n12:17134 n13:C07630 n14:D00580 n15:46507915
n3:mechanismOfAction
Sulfadoxine is a sulfa drug, often used in combination with pyrimethamine to treat malaria. This medicine may also be used to prevent malaria in people who are living in, or will be traveling to, an area where there is a chance of getting malaria. Sulfadoxine targets Plasmodium dihydropteroate synthase and dihydrofolate reductase. Sulfa drugs or Sulfonamides are antimetabolites. They compete with para-aminobenzoic acid (PABA) for incorporation into folic acid. The action of sulfonamides exploits the difference between mammal cells and other kinds of cells in their folic acid metabolism. All cells require folic acid for growth. Folic acid (as a vitamin) diffuses or is transported into human cells. However, folic acid cannot cross bacterial (and certain protozoan) cell walls by diffusion or active transport. For this reason bacteria must synthesize folic acid from p-aminobenzoic acid.
n3:packager
n5:271B6437-363D-11E5-9242-09173F13E4C5 n5:271B6438-363D-11E5-9242-09173F13E4C5
n3:synonym
Sulforthomidine Sulfadoxine Sulfadoxina Sulphormethoxine 4-Sulfanilamido-5,6-dimethoxypyrimidine Sulphadoxine Sulfadoxinum
n3:IUPAC-Name
n4:271B643D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6443-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6442-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B643F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6440-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6441-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B643B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6454-363D-11E5-9242-09173F13E4C5 n4:271B6439-363D-11E5-9242-09173F13E4C5 n4:271B643C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B643A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6449-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B644A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6444-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6445-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6447-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6446-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6448-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
2447-57-6
n3:Bioavailability
n4:271B644F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6451-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6452-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6453-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B644E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B644D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6450-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B643E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B644B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B644C-363D-11E5-9242-09173F13E4C5